Vaccines and therapeutics for Andes hantavirus Authors: Alina Tscherne, Nico Joel Halwe, Florian Krammer Published: 2026 ABSTRACT AbstractThe recent outbreak of Andes hantavirus (ANDV) on a cruise ship has raised concerns. While it is unlikely that hantaviruses will cause the next pandemic, increasing numbers of hantavirus infections are observed globally over the last years and the tendency of ANDV to transmit from human to-human is concerning. To date, vaccines or therapeutics are not available for ANDV, underscoring the urgent need to develop effective countermeasures. Background Hantaviruses belong to the family Hantaviridae within the order Bunyavirales and are endemic worldwide. The negative-sense, single-stranded RNA genome is split into three segments, which encode for the surface glycoprotein (GnGc), the nucleoprotein (N), the RNA-dependent RNA polymerase (L), and a non-structural protein (NSs; encoded by some hantaviruses such as Puumala hantavirus (PUUV), or Andes hantavirus (ANDV)). Each hantavirus typically infects one specific host species, in which they cause persistent, mostly apathogenic infections with viral shedding in excreta and body fluids. Infections of humans are reported frequently, with more than 100,000 estimated cases annually1 and are typically caused by inhalation of contaminated excreta of rodents or by direct contact with rodents or their excreta or body fluids. Hantaviruses cause zoonotic diseases that clinically manifest in two forms: 1) hemorrhagic fever with renal syndrome (HFRS), found in Eurasia and caused by Old World hantaviruses, and 2) hantavirus cardiopulmonary syndrome (HCPS, also called hantavirus pulmonary syndrome or HPS), found in North- and South America and caused by New World hantaviruses. So far, human-to-human transmission has only been reported for a single species, for ANDV, a highly pathogenic HCPS-causing hantavirus with a case fatality rate ranging between 30-50%2. First detected in 1995 in Argentina and Chile3, ANDV frequently causes infections in humans in the Americas, e.g., in the Austral Patagonian region (Chubut Province, Argentina) from 2018-2019 with 34 confirmed cases and 11 deaths4. Annually, around 100-200 cases of HCPS caused by ANDV are reported, mainly in Argentina and Chile5. Recently, ANDV was the causative agent of an outbreak on the cruise ship MV Hondius with 13 confirmed cases and three deaths so far and likely human-to-human transmission on board. This generated widespread media interest, as infected passengers traveled back to their respective home countries, which raised concerns about a potential new pandemic. Neither effective therapeutics nor licensed vaccines are available against ANDV and most of the other members of the hantavirus family. Reasons are, e.g., the low level and durability of immunity induced by existing vaccine candidates, inefficient in vitro cell culture systems for inactivated vaccine production, lack of suitable animal models that mimic human disease outcomes, and the lack of funding, as the general commercial interest in developing effective measures against such a rare disease is very low. Vaccines in preclinical and clinical development So far, there are no ANDV vaccines licensed for human use. In China and South Korea, inactivated hantavirus preparations which specifically target Hantaan virus (HTNV) and Seoul hantavirus (SEOV) are used6. The licensed vaccine used in South Korea, named “Hantavax”, has already been developed in the late 1980s, and has received approval for human use after seroconversion in humans had been confirmed by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay (IFA) as a surrogate of efficacy. However, in different clinical trials (reviewed in7), the immunity induced by the vaccine was considerably low, waned within months, and was not cross-reactive to other hantaviruses. Furthermore, the vaccine raised safety concerns as HTNV is propagated in the brain of suckling mice8,9. For ANDV, viral-vectored10,11, DNA-based12, RNA-based13, and nanoparticle-based vaccine candidates14 (Fig. 1A), mainly targeting the ANDV glycoprotein and/or nucleoprotein, have been tested successfully in preclinical models, such as the Syrian hamster (the only small animal model for lethal ANDV infection to date), or non-human primates. The vaccine candidates induced binding and neutralizing antibody responses and cytotoxic T cells after one or multiple immunizations which was associated e.g., with a complete or partial protection against lethal ANDV infection, the induction of cross-reactive immunity against other hantaviruses such as PUUV, Sin Nombre hantavirus (SNV) or HTNV, or the induction of a recall response following long-range booster. Overview of the current status of Andes hantavirus (ANDV)- specific countermeasures and challenges. A Vaccines and antivirals in preclinical and clinical evaluation. The numbers in the brackets indicate how many ANDV-specific candidate vaccines or antivirals are currently being tested in preclinical and clinical studies. Although one DNA-based vaccine candidate, small molecules such as Ribavirin, and immune sera have already been tested in clinical studies, additional preclinical studies are being performed for further characterization (e.g., administration dosages and intervals). B Current challenges associated for the development of effective countermeasures against ANDV. ANDV: Andes hantavirus. rVSV: recombinant vesicular stomatitis virus. mAbs: monoclonal antibodies. n/a: not applicable/unclear clinical phase. Created with BioRender.com. Recently, a DNA-based vaccine encoding ANDV glycoprotein15 has successfully been tested in a small number of healthy individuals in a phase I clinical trial (NCT03682107), in which the vaccine has been proven safe and immunogenic (induction of neutralizing antibody responses) after 3 or 4 immunizations using needle-free injections as delivery system. Therapeutics Due to a lack of approved therapeutics, treatment of HFRS and HCPS relies predominately on the management of clinical symptoms, including hemodialysis, oxygenation, fluid balancing and/or mechanical ventilation16,17. Ribavirin (1-b-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide), a guanosine analogue with a broad spectrum virostatic activity against both DNA and RNA viruses, showed only limited suitability as treatment of HFRS in clinical studies18. While Ribavirin has been tested successfully in in vitro cell culture models and in vivo animal models (e.g., Syrian hamsters) against ANDV, the suitability of Ribavirin as treatment of HCPS in humans could not be confirmed so far and still remains controversial19. Activation of vasoactive mediators, such as vascular endothelial growth factor (VEGF), is thought to cause increased microvascular permeability following ANDV infection. The activation may lead to a degradation of vascular endothelial cadherin molecule (VE-cadherin) which eventually disrupts cell to cell junctions contributing to a loss of the vascular barrier function20. Vandetanib, a kinase inhibitor blocking VEGF-receptor 2 activation and currently used as treatment against thyroid cancer, has been shown to delay symptom onset in Syrian hamster when given prior to ANDV exposure21. Presumably, the block of VEGF-receptor activation reduces the degradation of VE-cadherin thereby maintaining the vascular barrier function21. However, clinical data are missing to confirm the suitability of Vandetanib as treatment of HCPS. Clinical data from cancer patients treated with Vandetanib already indicate severe side effects22, making a clinical use of Vandetanib against HCPS in its current form very unlikely. Favipiravir (T-705, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a pyrazine derivative, with a broad spectrum antiviral activity against different RNA viruses via inhibition of the viral RNA polymerase, has been shown to reduce viral load and to prevent lethal disease in ANDV-infected Syrian hamsters when given daily after exposure23. However, clinical data on the suitability of favipiravir as treatment of HCPS are lacking. In addition to small molecules, monoclonal antibodies (mAbs) and immune sera of HCPS survivors are promising approaches against HCPS. In preclinical models, mAbs (e.g., JL16, MIB22, SAB-163, ADI-65534, HAP-2D11, KL-AN-4E1, KL-AN-5E8, KL-HAP-6B12) either derived from HCPS/HFRS survivors or mice or the plasma of immunized transchromosomic bovines (TcB) showed neutralizing activity against ANDV and other hantaviruses and provided protection against lethal ANDV infection in Syrian hamsters24–28. As for the small molecule drugs, no clinical data are available to confirm the suitability of mAbs, given individually or as cocktail, as potential treatment of HCPS in humans. Plasma of HCPS survivors with high neutralizing antibody titers was evaluated in a small non-randomized multicenter trial, confirming safety and a slight decrease in case fatality rate29. However, larger studies involving more study participants are necessary to further evaluate the suitability of convalescent sera as treatment option of HCPS. Current challenges in developing effective countermeasures Hantavirus disease has already been described during the Korean War in the 1950s, and research on developing effective vaccines and antivirals is ongoing since then. However, there are several roadblocks for the development of effective countermeasures against ANDV, and other members of the hantavirus family (Fig. 1B): 1) The lack of funding due to a low commercial interest, as ANDV infections are rare (only a few hundred cases per year) so far, and limited globally to the Americas. 2) Suitable in vitro cell culture models are lacking. Thus, hantaviruses grow only to low titers and often do not cause cytopathic effects (CPE), which limits efficient production of inactivated virus vaccines. 3) Attempts to create infectious virus clones via reverse genetics failed so far, limiting research on hantaviruses, and the development of live attenuated vaccines. 4) Infections with ANDV are rare, which makes the evaluation of vaccine candidates and antivirals in late-stage efficacy trials difficult since a large number of study participants are required. 5) The large GnGc glycoprotein, which is the main target of neutralizing antibodies, is difficult to express and to recombinantly produce as antigen due to protein misfolding, instability or cytotoxic effects on host cells30. 6) Current existing vaccine platforms need to be optimized to induce a strong and durable immune response. This includes a rational design of target antigens for the vaccine candidates, but also the administration route. Hantaviruses establish infections in humans mostly via the respiratory tract; however, most candidate vaccines are administered via the intramuscular route and not via the mucosal route (e.g., intranasal application) to induce a strong mucosal immune response. Conclusion Due to climate change, the spread of the rodent host reservoirs to urban areas, and the close contact of humans to rodents due to outdoor activities (e.g., camping, hiking, forest work etc.), an increase in hantavirus infections is expected in the coming years. In addition, there are open questions about the potential of ANDV to cause larger outbreaks via human-to-human transmission. Thus, the development of effective countermeasures against ANDV, but also other hantaviruses, is urgently needed. The current outbreak of ANDV may contribute to a change of perspective among funders to invest in research and development focusing on this highly neglected virus family. At the very least, large batches of polyclonal human plasma or mAbs should be produced and stockpiled in a quality that allows compassionate use in potential future outbreaks. Acknowledgements Work in the Krammer laboratory at the Ignaz Semmelweis Institute at the Medical University of Vienna is supported by institutional funds. Work at the Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness at the Medical University of Vienna is funded by the Ludwig Boltzmann Gesellschaft (LBG) and the institute’s partners: the Medical University of Vienna (host institution), the City of Vienna and the Austrian National Public Health Institute (GÖG). Author contributions A.T.: Writing- Original Draft, Writing-Main Manuscript. N.J.H.: Writing- Review & Editing. F.K.: Conceptualization, Writing- Review & Editing, Funding Acquisition. Data availability No datasets were generated or analyzed for this manuscript. Competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list FK as co-inventor and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. FK is co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with Sanofi on SARS-CoV-2 variant monitoring. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Alina Tscherne, Email: alina.tscherne@meduniwien.ac.at. Florian Krammer, Email: florian.krammer@meduniwien.ac.at. References Associated Data Data Availability Statement No datasets were generated or analyzed for this manuscript.